Current primary open-angle glaucoma treatments and future directions.
Current primary open-angle glaucoma treatments and future directions.
复制标题
DOI：
10.2147/opth.s32933
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
Mousa SA
中科院分区：
文献类型：
--
作者：
Beidoe G;Mousa SA
原发性开角型青光眼（POAG）是致盲的主要原因，目前尚无治愈方法。该疾病的管理集中于使用当前类别的药物如前列腺素类似物、β-阻滞剂、α-激动剂和碳酸酐酶抑制剂来降低眼内压（IOP）。这些治疗并不能帮助所有的病人。一些患者继续经历视神经恶化，即使他们的IOP在正常范围内。关于POAG进展中涉及的其他病理生理过程（如氧化应激、血管功能障碍和视网膜细胞凋亡）的新观点已经浮出水面，并且提倡用药物如美金刚、双（7）-他克林、尼莫地平和米托孕酮进行预防性治疗。本文综述了POAG目前的治疗方法和建议。一些被提议的药物（双（7）-他克林、尼莫地平、维生素E等）已经显示出良好的前景，大多数在各种临床试验中作为单一疗法。建议对当前和拟定药物进行进一步的并行给药稳健性试验并进行评价。
Primary open-angle glaucoma (POAG) is a leading cause of blindness with no known cure. Management of the disease focuses on lowering intraocular pressure (IOP) with current classes of drugs like prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. These treatments have not helped all patients. Some patients continue to experience deterioration in the optic nerve even though their IOPs are within the normal range. New views have surfaced about other pathophysiological processes (such as oxidative stress, vascular dysfunction, and retinal cell apoptosis) being involved in POAG progression, and adjunctive treatments with drugs like memantine, bis(7)-tacrine, nimodipine, and mirtogenol are advocated. This review examines the current and proposed treatments for POAG. Some of the proposed drugs (bis(7)-tacrine, nimodipine, vitamin E, and others) have shown good promise, mostly as monotherapy in various clinical trials. It is recommended that both the current and proposed drugs be put through further robust trials in concurrent administration and evaluated.